Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Race Oncology Ltd. ( (AU:RAC) ) just unveiled an announcement.
Racura Oncology has entered a collaboration with Emory University to study its lead candidate (E,E)-bisantrene (RC220) in osimertinib-resistant EGFR-mutated non-small cell lung cancer, leveraging Emory’s specialised cell and mouse models and the expertise of lung cancer resistance specialist Professor Shi-Yong Sun. Early preclinical data from the partnership show significant synergy between RC220 and AstraZeneca’s blockbuster drug Tagrisso (osimertinib), supporting Racura’s HARNESS-1 Phase 1a/b trial that aims to delay or prevent treatment resistance in EGFRm NSCLC patients, potentially strengthening Racura’s scientific platform and enhancing its positioning for engagement with clinicians, regulators and prospective pharma partners in a large and growing market for EGFR-targeted therapies.
The most recent analyst rating on (AU:RAC) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.
More about Race Oncology Ltd.
Racura Oncology Limited is an Australian clinical-stage oncology company focused on developing (E,E)-bisantrene (RC220/RCDS1) as a targeted therapy for difficult-to-treat cancers. Its current programs centre on combination approaches in epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC), aiming to overcome or delay resistance to standard-of-care treatments such as third-generation tyrosine kinase inhibitors.
Average Trading Volume: 269,386
Technical Sentiment Signal: Buy
Current Market Cap: A$501M
Learn more about RAC stock on TipRanks’ Stock Analysis page.